KLK3 and prostate carcinoma: A double-blind, randomized, placebo-controlled multicenter trial with sulforaphane in 78 patients conducted by Cipolla et al. in patients with recurrent prostate cancer showed that individuals administered 60 mg of sulforaphane for six months had on average an 86% longer PSA doubling time [11].